In Vitro Inhalation Testing:
Revolutionizing Inhalation Product Safety
In the world of product safety and environmental health, assessing the potential risks associated with inhalable products has always been a complex challenge. Commercial nebulizer applications—frequently used for disinfection and ambient scenting, release aerosols into the air that could be potentially harmful.
Understanding the possible adverse acute inhalation effects of these aerosols is crucial for ensuring consumer safety. A recent study by Ritter et al. (2023) explores an innovative in vitro inhalation approach designed to accurately estimate the potential acute toxicity of aerosols from commercial nebulizers.
The Goals of Modern In Vitro Inhalation Studies
The study sought to bridge the gap between laboratory testing and real-world human exposure scenarios. To achieve this, researchers focused on several key objectives:
Characterize commercial aerosols and estimate realistic human exposure.
Evaluate acute biological effects through advanced in vitro inhalation models.
Generate dose-response data to determine in vitro lowest observable adverse effect levels (LOAELs).
Correlate in vitro data with human lung deposition using a quantitative in vitro to in vivo extrapolation (QIVIVE) approach.
Advanced Methodology: Air-Liquid Interface and the expoCube®
To demonstrate the feasibility of this QIVIVE approach, the researchers conducted a case study using two realistic test materials commonly found in commercial nebulizers, even though detailed knowledge of their chemical composition was limited.
The study utilized an acute in vitro inhalation setup featuring air-liquid interface (ALI) A549-cells cultivated within an optimized exposure system known as the expoCube®.
This innovative methodology exposed the cells directly to the aerosols, allowing researchers to analyze highly relevant biological endpoints, including:
Cell viability
Mitochondrial membrane potential
Cellular stress levels
IL-8 inflammatory release
Case Study Findings: Bridging the Gap with QIVIVE
Figure 1 – expoCube
The expoCube® case study successfully yielded dose-responsive effects within a sub-toxic dose range. These effects were primarily attributed to the main component of one of the test materials present in the aerosol phase.
Crucially, the QIVIVE calculations indicated a safety factor of at least 256 between the in vitro LOAEL and the estimated acute human lung exposure for this specific test material. In essence, this approach allowed researchers to quantify the potential adverse effects associated with aerosol exposure, proving effective even when detailed knowledge of the product’s exact composition was restricted.
The Future of Non-Target In Vitro Testing
This publication highlights the immense value of a non-target in vitro inhalation testing approach, especially when dealing with complex products of unknown composition.
By enabling researchers to gather vital information on biological effects, in vivo relevance, and the contributions of individual aerosol compounds, these methods are dramatically advancing product safety and environmental health assessments. As the industry accumulates more knowledge from diverse applications, in vitro to in vivo predictions will only become more refined, ultimately leading to improved study designs, better result interpretation, and safer consumer products.
Reference
Development of a non-target strategy for evaluation of potential biological effects of inhalable aerosols generated during purposeful room conditioning using an in vitro inhalation model. (2023). Ritter, D., et al. Inhalation Toxicology, 35: 11-12
Resources
Empowering researchers
Welcome to SCIREQ’s knowledge center. You can find everything from software registration to document downloads to complete list of SCIREQ publications in this section. Everything you need to get the most out of your SCIREQ system.